What is the target market for these biomarkers and their subsequent product development?
There are several specific target markets for the biomarkers discovered by Power3 Medical. The first is diagnostic companies. These companies are interested in identified biomarkers or prototyped diagnostic tests developed from the biomarkers. The world diagnostic market was estimated at over $19 billion in 2001 (Clinical/Merrill Lynch, 2000). The second is pharmaceutical companies looking for drug targets identified by a discovered biomarker. “The value of cooperation agreements between pharmaceutical and proteomic corporations is now at about 1 billion Dollars,” reports Kathy Austin, Technology Research analyst at Frost & Sullivan. “The investments pay rich dividends even if the collaboration offers the pharmaceutical corporation in question only two or three target molecules.” Although today the Power3 Medical customer is a diagnostic and pharmaceutical company, the end user is always the patient. To that end, Power3 Medical may choose to develop and market our own screening test, a
